We designed our study to investigate the effects of iron isomaltoside, a clinically approved intravenous iron compound, on the course of disease, therapeutic efficacy of anti-cancer immunotherapies and anti-tumor response of CD4+ and CD8+ tumor infiltrating T cells in the E0771 breast cancer model (61). Here, CD8A is linked to neoplasm.